Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$65.50 -0.5%	$64.31	$52.50 ▼ $77.00	$1.42B	0.55	311,463 shs	325,389 shs
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.09	$5.20 ▼ $10.67	$1.17B	1.15	1.35 million shs	4.36 million shs
KURA Kura Oncology	$5.67 -1.0%	$6.17	$5.41 ▼ $23.48	$490.88M	0.4	1.24 million shs	3.33 million shs
SAVA Cassava Sciences	$1.75 -4.4%	$1.91	$1.15 ▼ $42.20	$84.54M	-1.99	2.98 million shs	5.99 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	-0.09%	+12.43%	-3.12%	+0.02%
AUPH Aurinia Pharmaceuticals	0.00%	+11.20%	+8.14%	+4.22%	+56.81%
KURA Kura Oncology	0.00%	-3.08%	-2.58%	-19.57%	-72.48%
SAVA Cassava Sciences	0.00%	-12.06%	-14.22%	+6.06%	-90.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.5926 of 5 stars	2.5	1.0	3.3	1.7	3.3	1.3
AUPH Aurinia Pharmaceuticals	2.7534 of 5 stars	3.5	1.0	0.0	2.8	0.8	1.9
KURA Kura Oncology	4.5336 of 5 stars	4.4	3.0	4.7	2.0	0.8	0.6
SAVA Cassava Sciences	4.3183 of 5 stars	3.3	3.0	4.7	3.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	22.33% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	332.10% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	3,014.29% Upside

Current Analyst Ratings Breakdown

Latest AUPH, KURA, ANIP, and SAVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00
4/11/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
4/8/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.31	$7.60 per share	8.62	$19.11 per share	3.43
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	28.01	$2.68 per share	3.22
KURA Kura Oncology	$53.88M	9.11	N/A	N/A	$5.32 per share	1.07
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.56	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/6/2025 (Estimated)

Latest AUPH, KURA, ANIP, and SAVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
KURA Kura Oncology	0.02	8.07	8.07
SAVA Cassava Sciences	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
AUPH Aurinia Pharmaceuticals	36.83%
KURA Kura Oncology	N/A
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
AUPH Aurinia Pharmaceuticals	12.20%
KURA Kura Oncology	6.40%
SAVA Cassava Sciences	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable

AUPH, KURA, ANIP, and SAVA Headlines

Recent News About These Companies

SAVA Stock Price for Cassava Sciences Inc - Morningstar

June 28 at 11:21 PM | morningstar.comM

Why cassava could be a great addition to a balanced diet

June 26 at 5:49 PM | msn.com

Two Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 5, 2025 | marketbeat.com

Two Sigma Advisers LP Invests $1.43 Million in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 1, 2025 | marketbeat.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava partners with Zindi to give African AI developers better tools

May 15, 2025 | techzim.co.zwT

Cassava Sciences Inc.

May 15, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.comK

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.comT

Cassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU Ecosystem

May 12, 2025 | devdiscourse.comD

New report finds concerning levels of lead in popular cassava items

May 12, 2025 | yahoo.com

Cassava takes next step for African AI

May 12, 2025 | htxt.co.zaH

Cassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovation

May 12, 2025 | zawya.comZ

Cassava Reports Q1 2025 Financials Results, Provides Business Update

May 9, 2025 | finance.yahoo.com

Zindi Teams Up with Cassava to Spotlight African AI Talent

May 6, 2025 | msn.com

Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation

May 5, 2025 | msn.com

Cassava Consciousness from The Tamarind Galaxy part two

May 1, 2025 | modernghana.comM

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025 | globenewswire.com

Targeted and random mutagenesis of cassava brown streak disease susceptibility factors reveal molecular determinants of disease severity

April 30, 2025 | elifesciences.orgE

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, KURA, ANIP, and SAVA Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$65.50 -0.31 (-0.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$65.46 -0.05 (-0.07%)

As of 06/27/2025 04:34 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.62 -0.02 (-0.23%)

As of 06/27/2025 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Kura Oncology NASDAQ:KURA

$5.67 -0.06 (-1.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.11 (+1.94%)

As of 06/27/2025 06:33 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Cassava Sciences NASDAQ:SAVA

$1.75 -0.08 (-4.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.80 +0.05 (+2.86%)

As of 06/27/2025 07:57 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time